Taobao
. : MLB. : 15-19 20-24 25-29 30-34. : . : . : . : . : . : 32CPB1-50L 32CPB1-50P 32CPB1-50N 32CPB1-10P 32CPB1-07U 32CPB1-50R 32CPB1-43R 32CPB1-07B 32CPB1- 50R 32CPB1-50W 32CPB1- 07U 32CPB7-50L 32CPB7-50G
Get a Quote
Liming · . Liming. . . more >. ：025-58139661 E-mail：[email protected] ：30 …
Get a Quote
NY/T 391-2000 __
Kefid · NY/T 751-2017。,,,,、。,,.、,,()、,,,,,﹑、,.
Get a Quote
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
Liming · The incidence of NY‐ESO‐1 is also interesting to compare between groups in different countries. For example, non‐small cell lung cancer (NSCLC) appears to have a 20–25% expression rate of NY‐ESO‐1 in most US studies, while it is only rarely found in Japan ().Squamous cell carcinoma of the lung is more common in Japan while adenocarcima is …
Get a Quote
-
. : MLB. : 15-19 20-24 25-29 30-34. : . : . : . : . : . : 32CPB1-50L 32CPB1-50P 32CPB1-50N 32CPB1-10P 32CPB1-07U 32CPB1-50R 32CPB1-43R 32CPB1-07B 32CPB1- 50R 32CPB1-50W 32CPB1- 07U 32CPB7-50L 32CPB7-50G
Get a Quote
_ - sina
Kefid · NY/T 391-2000 201441NY/T 391-2013 （Kefid）。、、、
Get a Quote
NY-ESO-1–specific TCR–engineered T cells mediate …
Liming · Assays for NY-ESO-1 and LAGE-1 expression and persistence, trafficking and function of gene-modified T cells. Research sample processing, freezing, and laboratory analyses were performed in the
Get a Quote
NY/T 751-2021 __
Liming · NY/T 751-2017。,,,,、。,,.、,,()、,,,,,﹑、,.
Get a Quote
NY/T 391-2000 __
Liming · NY/T 391-2000 201441NY/T 391-2013 （Liming）。、、、
Get a Quote